A Agilent Technologies (A) Insider Trading, Ownership & Congress Trades
Medical Devices · Laboratory analytical instruments · CIK 0001090872
Congress · 1Form 144 · 1
Insider buyers, 180 days
0
Funds added, last quarter
604
13F, latest reported quarter
What the filings say about A
Insiders, 180 days
-$312.6K net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-09-09
Planned sales (Form 144), 90 days
$96.0K
1 notice
Agilent Technologies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, AGILENT TECHNOLOGIES, INC. insiders sold a net $312.6K of stock across 73 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 29, 2026.
- The trade is 12.9% of the 4,923 shares held after it.
- No other insider sold within 30 days.
- 604 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dolsten Mikael sold about $96.0K of A on Sep 4, 2026; 604 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 1, 2025.
- The trade is 28.8% of the 5,548 shares held after it.
- No other insider sold within 30 days.
- 604 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dolsten Mikael sold about $216.7K of A on May 29, 2026; 604 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 52.3% of the 4,973 shares held after it.
- 2 other insiders sold within 30 days.
- 604 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Dolsten Mikael sold about $389.5K of A on Dec 1, 2025; 2 other insiders sold within 30 days and 604 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (1 buy, 12 sales), the last on Mar 17, 2025.
- The trade is 9.4% of the 31,845 shares held after it.
- 2 other insiders sold within 30 days.
- 604 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: V.P., Corporate Controller Gonsalves Rodney sold about $465.0K of A on Nov 26, 2025; 2 other insiders sold within 30 days and 604 funds added in the latest 13F quarter.Context
- 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Nov 12, 2025.
- The trade is 2.8% of the 32,058 shares held after it.
- 2 other insiders sold within 30 days.
- 604 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO MCDONNELL PADRAIG sold about $130.5K of A on Nov 18, 2025; 2 other insiders sold within 30 days and 604 funds added in the latest 13F quarter.73 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$312.6K over 180 days
-$96.0K over 90 days
below 53% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
604 funds bought in last quarter
more than 96% of Medical Devices
Revenue
+6.7% year over year
below 60% of Medical Devices
Margin
18.8% net margin
more than 92% of Medical Devices
Buybacks
$295.0M repurchased, FY to 2026-07-31
more than 76% of Medical Devices
Short interest
1.9% of the float short (float per yahoo 2026-10-26) · 1.8 days to cover · settled 2026-09-30
below 67% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch A
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+21.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns A: institutional holders (13F)
13F holdings, latest reported quarter
25,599,001 sh
$3.4B
18,449,861 sh
$2.5B
14,442,441 sh
$1.9B
12,854,230 sh
$1.7B
10,010,867 sh
$1.4B
Congress trades in A
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-09-09 · disclosed 16 days later
$15,001 - $50,000
Sold 2025-09-23 · disclosed 316 days later
$1,001 - $15,000
Bought 2025-09-23 · disclosed 316 days later
$1,001 - $15,000
Sold 2025-07-16 · disclosed 28 days later
$1,001 - $15,000
Bought 2025-06-17 · disclosed 57 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
A planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Dolsten Mikael
Filed 2026-09-04
$96.0K
A mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
SUMMITRY EQUITY FUND
$3.6M position · as of 2026-07-31
4.9%
First Trust Water ETF
$84.2M position · as of 2026-06-30
4.5%
Scharf Global Opportunity ETF
$6.7M position · as of 2026-06-30
4.2%
Madison Covered Call ETF
$1.3M position · as of 2026-06-30
3.9%
Calvert Equity Fund
$130.6M position · as of 2026-06-30
3.9%
Invesco Water Resources ETF
$77.4M position · as of 2026-07-31
3.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Homeland Security
THIS ACQUISITION IS FOR THE PROCUREMENT OF UP TO 174 BULK RESOLUTION TECHNOLOGY (BRT) SYSTEMS, INCLU · 2026-09-30
$10.7M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$12.8M
$14.6M
$3.8M
+48%
+94%
2023
$16.0M
$1.0M
$3.7M
+3%
+34%
2022
$16.6M
$10.5M
$4.2M
+37%
+30%
2021
$16.0M
$31.8M
$3.8M
+55%
+40%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $312.6K sold by insiders over 180 days, 604 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $96.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
A financials
Revenue growth
+6.7%
XBRL, annual
Net margin
18.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.4B
four quarters, 2025-08-01 to 2026-07-31
Revenue, TTM A
| FY Oct 2025 | $6.9B |
| FY Oct 2024 | $6.5B |
| FY Oct 2023 | $6.8B |
| FY Oct 2022 | $6.8B |
| FY Oct 2021 | $6.3B |
| Jul 2026 | $1.9B |
| Apr 2026 | $1.8B |
| Jan 2026 | $1.8B |
| Oct 2025 | $1.9B |
| Jul 2025 | $1.7B |
| Apr 2025 | $1.7B |
| Jan 2025 | $1.7B |
| Oct 2024 | $1.7B |
At each fiscal year end
Single quarter
Net margin, TTM
+19.5%
net income over revenue, 2025-08-01 to 2026-07-31
Net margin, TTM A
| FY Oct 2025 | +18.8% |
| FY Oct 2024 | +19.8% |
| FY Oct 2023 | +18.1% |
| FY Oct 2022 | +18.3% |
| FY Oct 2021 | +19.1% |
| Jul 2026 | +19.3% |
| Apr 2026 | +18.5% |
| Jan 2026 | +17.0% |
| Oct 2025 | +23.3% |
| Jul 2025 | +19.3% |
| Apr 2025 | +12.9% |
| Jan 2025 | +18.9% |
| Oct 2024 | +20.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.3B
operating cash flow minus capex, 2025-08-01 to 2026-07-31
Free cash flow, TTM A
| FY Oct 2025 | $1.2B |
| FY Oct 2024 | $1.4B |
| FY Oct 2023 | $1.5B |
| FY Oct 2022 | $1.0B |
| FY Oct 2021 | $1.3B |
| Jul 2026 | $439.0M |
| Apr 2026 | $201.0M |
| Jan 2026 | $175.0M |
| Oct 2025 | $452.0M |
| Jul 2025 | $259.0M |
| Apr 2025 | $107.0M |
| Jan 2025 | $334.0M |
| Oct 2024 | $388.0M |
At each fiscal year end
Single quarter
Debt to equity
0.54x
long-term 2026-07-31 plus current 2026-07-31; equity 2026-07-31
Debt to equity A
| FY Oct 2025 | 0.50x |
| FY Oct 2024 | 0.57x |
| FY Oct 2023 | 0.47x |
| FY Oct 2022 | 0.52x |
| FY Oct 2021 | 0.51x |
| Jul 2026 | 0.54x |
| Apr 2026 | 0.47x |
| Jan 2026 | 0.49x |
| Oct 2025 | 0.50x |
| Jul 2025 | 0.54x |
| Apr 2025 | 0.57x |
| Jan 2025 | 0.56x |
| Oct 2024 | 0.57x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.41x
TTM operating cash flow over long-term 2026-07-31 plus current 2026-07-31
Cash flow to debt A
| FY Oct 2025 | 0.46x |
| FY Oct 2024 | 0.52x |
| FY Oct 2023 | 0.65x |
| FY Oct 2022 | 0.47x |
| FY Oct 2021 | 0.54x |
| Jul 2026 | 0.41x |
| Apr 2026 | 0.43x |
| Jan 2026 | 0.42x |
| Oct 2025 | 0.46x |
| Jul 2025 | 0.44x |
| Apr 2025 | 0.45x |
| Jan 2025 | 0.50x |
| Oct 2024 | 0.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+21.0%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on equity A
| FY Oct 2025 | +20.6% |
| FY Oct 2024 | +22.0% |
| FY Oct 2023 | +22.2% |
| FY Oct 2022 | +23.5% |
| FY Oct 2021 | +23.6% |
| Jul 2026 | +21.0% |
| Apr 2026 | +21.3% |
| Jan 2026 | +19.9% |
| Oct 2025 | +20.6% |
| Jul 2025 | +19.9% |
| Apr 2025 | +18.9% |
| Jan 2025 | +20.6% |
| Oct 2024 | +22.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+11.0%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on assets A
| FY Oct 2025 | +10.6% |
| FY Oct 2024 | +11.4% |
| FY Oct 2023 | +11.6% |
| FY Oct 2022 | +11.8% |
| FY Oct 2021 | +11.9% |
| Jul 2026 | +11.0% |
| Apr 2026 | +11.2% |
| Jan 2026 | +10.4% |
| Oct 2025 | +10.6% |
| Jul 2025 | +10.5% |
| Apr 2025 | +10.1% |
| Jan 2025 | +11.0% |
| Oct 2024 | +11.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+15.5%
operating income after a 13.1% effective tax rate, over long-term 2026-07-31 plus current 2026-07-31 plus average of 2025-07-31 and 2026-07-31 minus cash
Return on invested capital A
| FY Oct 2025 | +16.6% |
| FY Oct 2024 | +16.2% |
| FY Oct 2023 | +17.9% |
| FY Oct 2022 | +19.7% |
| FY Oct 2021 | +18.7% |
| Jul 2026 | +15.5% |
| Apr 2026 | +16.7% |
| Jan 2026 | +16.0% |
| Oct 2025 | +16.6% |
| Jul 2025 | +16.0% |
| Apr 2025 | +14.9% |
| Jan 2025 | +16.0% |
| Oct 2024 | +16.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+14.9%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
Return on capital employed A
| FY Oct 2025 | +14.5% |
| FY Oct 2024 | +15.6% |
| FY Oct 2023 | +15.1% |
| FY Oct 2022 | +18.3% |
| FY Oct 2021 | +15.7% |
| Jul 2026 | +14.9% |
| Apr 2026 | +14.9% |
| Jan 2026 | +14.1% |
| Oct 2025 | +14.5% |
| Jul 2025 | +15.2% |
| Apr 2025 | +14.9% |
| Jan 2025 | +15.3% |
| Oct 2024 | +15.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
34.71x
close 2026-10-26 over four quarters of diluted EPS, 2025-08-01 to 2026-07-31
P/E, trailing A
| FY Oct 2025 | 32.10x |
| FY Oct 2024 | 29.42x |
| FY Oct 2023 | 24.61x |
| FY Oct 2022 | 33.10x |
| FY Oct 2021 | 40.07x |
| Jul 2026 | 27.29x |
| Apr 2026 | 23.25x |
| Jan 2026 | 29.61x |
| Oct 2025 | 32.10x |
| Jul 2025 | 26.89x |
| Apr 2025 | 26.50x |
| Jan 2025 | 34.75x |
| Oct 2024 | 29.42x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$51.8B
market value at close 2026-10-26 on 2026-08-26 shares, plus long-term 2026-07-31 plus current 2026-07-31, minus cash 2026-07-31
Enterprise value A
| FY Oct 2025 | $43.1B |
| FY Oct 2024 | $39.5B |
| FY Oct 2023 | $31.4B |
| FY Oct 2022 | $42.7B |
| FY Oct 2021 | $48.9B |
| Jul 2026 | $41.3B |
| Apr 2026 | $34.2B |
| Jan 2026 | $39.5B |
| Oct 2025 | $43.1B |
| Jul 2025 | $34.5B |
| Apr 2025 | $32.7B |
| Jan 2025 | $45.2B |
| Oct 2024 | $39.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield A
| FY Oct 2025 | +2.8% |
| FY Oct 2024 | +3.7% |
| FY Oct 2023 | +4.9% |
| FY Oct 2022 | +2.5% |
| FY Oct 2021 | +2.7% |
| Jul 2026 | +3.2% |
| Apr 2026 | +3.3% |
| Jan 2026 | +2.6% |
| Oct 2025 | +2.8% |
| Jul 2025 | +3.3% |
| Apr 2025 | +3.9% |
| Jan 2025 | +3.0% |
| Oct 2024 | +3.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.85x
P/E over trailing EPS growth of 19%: four quarters to 2026-07-31 against the four to 2025-07-31
PEG, trailing A
| FY Oct 2025 | 10.94x |
| FY Oct 2024 | 5.37x |
| FY Oct 2023 | 51.44x |
| FY Oct 2022 | 5.20x |
| FY Oct 2021 | 0.57x |
| Jul 2026 | 1.46x |
| Apr 2026 | 1.04x |
| Jan 2026 | 8.07x |
| Oct 2025 | 10.94x |
| Jul 2025 | n/a |
| Apr 2025 | n/a |
| Jan 2025 | 8.57x |
| Oct 2024 | 5.37x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-10 | 2024-10 | 2023-10 | 2022-10 | |
|---|---|---|---|---|
| Revenue | $6.9B | $6.5B | $6.8B | $6.8B |
| Operating income | $1.5B | $1.5B | $1.4B | $1.6B |
| Net income | $1.3B | $1.3B | $1.2B | $1.3B |
| EPS (diluted) | 4.57 | 4.43 | 4.19 | 4.18 |
| Operating cash flow | $1.6B | $1.8B | $1.8B | $1.3B |
| Cash | $1.8B | $1.3B | $1.6B | $1.1B |
| Long-term debt | $3.0B | $3.3B | $2.7B | $2.7B |
| Buybacks | $425.0M | $1.1B | $575.0M | $1.1B |
| Dividends paid | $282.0M | $274.0M | $265.0M | $250.0M |
SEC XBRL, fiscal years, as known on 2026-10-27
A Stock Sonar score 6/7 axes
Find similar shapesCompareA ranks highest on profitability (84th percentile) and institutional and government (65th), and lowest on insider conviction (23rd), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
A filings, in plain words
Are Agilent Technologies insiders buying or selling A?
In the 180 days to 2026-10-27, Agilent Technologies insiders were net sellers, a net $312.6K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded A?
Yes. In the year to 2026-10-27, 1 House member disclosed buying A and 0 House members disclosed selling it; the latest on record is a purchase by Kevin Hern dated 2026-09-09.
Are there planned insider sales of A?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $96.0K of stock; the latest, by Dolsten Mikael, was filed 2026-09-04.
Read the full summary
In the 180 days to 2026-10-27, Agilent Technologies insiders were net sellers of A, a net $312.6K across purchases and sales reported on Form 4 by 1 seller. In the year to 2026-10-27, 1 member of Congress disclosed buying A and 0 members disclosed selling it; the latest on record is a purchase by Kevin Hern dated 2026-09-09. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $96.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
